Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose bevacizumab in recurrent glioblastoma
IRCT20160706028815N7Phase 2Recruiting
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Sabzevar University of Medical Sciences. Primary endpoint: Progression-free survival. Started Jul 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20160706028815N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160706028815N7.